Educational Symposium
HIF Inhibitors: Moving Beyond Erythropoietin and Iron Deficiency
October 24, 2020 | 01:00 PM - 02:00 PM
Location: Simulive
Session Description
Hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitors are the first novel class of medications to treat anemia since the approval of erythropoietin-stimulating agents in 1989. HIF-PH inhibitors are oral agents that treat anemia of CKD through multiple pathways; they have effects on inflammation and iron handling and decrease hepcidin levels. Advantages of HIF-PH inhibitors include decreased erythropoietin levels, increased absorption of oral iron, and access to existing iron stores.
Results of Phase 3 trials of HIF-PH inhibitors for the treatment of anemia in both dialysis-dependent and non–dialysis-dependent CKD have been promising. This symposium discusses the results of clinical trials and provides recommendations on the role of HIF-PH inhibitors in managing anemia of CKD.
Support is provided by an educational grant from Akebia Therapeutics, Inc. and Otsuka America Pharmaceutical, Inc.
Learning Objective(s)
- Compare the advantages and disadvantages of HIF-PH inhibitors with those of erythropoietin-stimulating agents for the management of anemia in CKD
- Determine the place for HIF-PH inhibitors in the management of anemia in CKD
Learning Pathway(s)
- Bone and Mineral Metabolism
- Chronic Kidney Disease
Presentations
-
Introduction
01:00 PM - 01:10 PM
-
Efficacy and Safety of HIF-PH Inhibitors in Treating Anemia of Non-Dialysis-Dependent CKD
01:10 PM - 01:35 PM
-
Efficacy and Safety of HIF-PH Inhibitors in Treating Anemia of Dialysis-Dependent CKD
01:35 PM - 02:00 PM
